|
[Related PubMed/MEDLINE]
Total Number of Papers: 532
|
|
|
|
|
[Display Entries]
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: sCT |
| Long Form |
: salmon calcitonin |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
A Novel Photoreactive Excipient to Probe Peptide-Matrix Interactions in Lyophilized Solids. |
pGlcN, pLeu |
| 2 |
2020 |
A thermo-sensitive injectable hydroxypropyl chitin hydrogel for sustained salmon calcitonin release with enhanced osteogenesis and hypocalcemic effects. |
HA, HPCH |
| 3 |
2020 |
Bone targeted delivery of salmon calcitonin hydroxyapatite nanoparticles for sublingual osteoporosis therapy (SLOT). |
HAP-NPs, SLOT |
| 4 |
2020 |
Design and Characterizations of Inhalable Poly(lactic-co-glycolic acid) Microspheres Prepared by the Fine Droplet Drying Process for a Sustained Effect of Salmon Calcitonin. |
FDD |
| 5 |
2020 |
Effects of a selective long-acting amylin receptor agonist on alcohol consumption, food intake and body weight in male and female rats. |
AMYRs, CTR |
| 6 |
2020 |
Effects of sub-chronic amylin receptor activation on alcohol-induced locomotor stimulation and monoamine levels in mice. |
CTR, LDTg, NAc, RAMPs, VTA |
| 7 |
2020 |
Flash Fabrication of Orally Targeted Nanocomplexes for Improved Transport of Salmon Calcitonin across the Intestine. |
DS, FNC, GC-T, GI |
| 8 |
2020 |
Investigation of salmon calcitonin in regulating fibrosis-related molecule production and cell-substrate adhesion in frozen shoulder synovial/capsular fibroblasts. |
CTRs, IHC, IL-1alpha, mRNA, PKA, PKC, SCFs, TGF-beta1 |
| 9 |
2020 |
Protection of Protein Drugs by Self-Emulsified Nanoemulsion Against Proteolysis. |
--- |
| 10 |
2020 |
RAMP1 and RAMP3 Differentially Control Amylin's Effects on Food Intake, Glucose and Energy Balance in Male and Female Mice. |
AP, CTR, IMI, RAMPs, RER |
| 11 |
2020 |
Salmon calcitonin distributes into the arcuate nucleus to a subset of NPY neurons in mice. |
AMY, AP, ARC, CTR, OVLT |
| 12 |
2020 |
Thermosensitive Hydrogel Based on Poly(2-Ethyl-2-Oxazoline)-Poly(D,L-Lactide)-Poly(2-Ethyl-2-Oxazoline) for Sustained Salmon Calcitonin Delivery. |
PPP, SEM |
| 13 |
2020 |
Viral depletion of calcitonin receptors in the area postrema: A proof-of-concept study. |
AAV, AP, CTR, GFP, NTS, RAMP |
| 14 |
2019 |
Activation of amylin receptors attenuates alcohol-mediated behaviours in rodents. |
--- |
| 15 |
2019 |
Additive and nonadditive effects of salmon calcitonin and omega-3 fatty acids on antioxidant, hematological and bone and cartilage markers in experimental diabetic-osteoarthritic rats. |
--- |
| 16 |
2019 |
An amylin analogue attenuates alcohol-related behaviours in various animal models of alcohol use disorder. |
NAc |
| 17 |
2019 |
Calcitonin native prefibrillar oligomers but not monomers induce membrane damage that triggers NMDA-mediated Ca2+-influx, LTP impairment and neurotoxicity. |
PFOs |
| 18 |
2019 |
Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss. |
DIO, DVC, GLP-1 |
| 19 |
2019 |
Controlled Delivery of Salmon Calcitonin Using Thermosensitive Triblock Copolymer Depot for Treatment of Osteoporosis. |
mPEG, PLGA |
| 20 |
2019 |
Development of a polysaccharide based multi-unit nanofiber mat for colon-targeted sustained release of salmon calcitonin. |
SCF |
| 21 |
2019 |
Enhancement of oral bioavailability of salmon calcitonin through chitosan-modified, dual drug-loaded nanoparticles. |
CS, FITC-sCT, NPs, PR |
| 22 |
2019 |
Hexapeptide-conjugated calcitonin for targeted therapy of osteoporosis. |
CTRs, HA |
| 23 |
2019 |
Inhibiting Human Calcitonin Fibril Formation with Its Most Relevant Aggregation-Resistant Analog. |
hCT |
| 24 |
2019 |
Salmon calcitonin exerts better preventive effects than celecoxib on lumbar facet joint degeneration and long-term tactile allodynia in rats. |
CLX, COMP, FJ, micro-CT, OA |
| 25 |
2019 |
The Interaction between Amyloid Prefibrillar Oligomers of Salmon Calcitonin and a Lipid-Raft Model: Molecular Mechanisms Leading to Membrane Damage, Ca2+-Influx and Neurotoxicity. |
--- |
| 26 |
2018 |
Calcitonin and Omega-3 Fatty Acids Exhibit Antagonistic and Non-Additive Effects in Experimental Diabetes. |
--- |
| 27 |
2018 |
Inhibition of the fibrillation of highly amyloidogenic human calcitonin by cucurbit[7]uril with improved bioactivity. |
hCT |
| 28 |
2018 |
Intra-articular delivery of a nanocomplex comprising salmon calcitonin, hyaluronic acid, and chitosan using an equine model of joint inflammation. |
CS, HA, IA, LPS, NPs |
| 29 |
2018 |
Salmon Calcitonin Attenuates Degenerative Changes in Cartilage and Subchondral Bone in Lumbar Facet Joint in an Experimental Rat Model. |
FJD, LBP |
| 30 |
2018 |
Synergistic and non-synergistic effects of salmon calcitonin and omega - 3 fatty acids on antioxidant, anti-inflammatory, and haematological indices in diabetic rats. |
DHA, DM, EPA |
| 31 |
2017 |
Amylin receptor activation in the ventral tegmental area reduces motivated ingestive behavior. |
VTA |
| 32 |
2017 |
Effects of Salmon Calcitonin and Omega - 3 Fatty Acids on Glucoregulatory Indices, Lipid Profile and Antioxidant Markers in Experimental Knee Osteoarthritis in Wistar Rats. |
DF, NO, OA |
| 33 |
2017 |
Effects of single or combined administration of salmon calcitonin and omega-3 fatty acids vs. diclofenac sodium in sodium monoiodoacetate-induced knee osteoarthritis in male Wistar rats. |
CAT, DF, IL-6, MDA, OA, SOD, UA |
| 34 |
2017 |
Growth-incompetent monomers of human calcitonin lead to a noncanonical direct relationship between peptide concentration and aggregation lag time. |
hCT |
| 35 |
2017 |
Supramolecular nanoparticles of calcitonin and dipeptide for long-term controlled release. |
--- |
| 36 |
2017 |
The area postrema (AP) and the parabrachial nucleus (PBN) are important sites for salmon calcitonin (sCT) to decrease evoked phasic dopamine release in the nucleus accumbens (NAc). |
AP, DA, NAc, PBN, VTA |
| 37 |
2016 |
A novel strategy for the preparation of porous microspheres and its application in peptide drug loading. |
PEG |
| 38 |
2016 |
Amorphous Calcium Carbonate Based-Microparticles for Peptide Pulmonary Delivery. |
AAT, ACC, HA |
| 39 |
2016 |
Calcitonin and Amylin Receptor Peptide Interaction Mechanisms: INSIGHTS INTO PEPTIDE-BINDING MODES AND ALLOSTERIC MODULATION OF THE CALCITONIN RECEPTOR BY RECEPTOR ACTIVITY-MODIFYING PROTEINS. |
AM, Amy, CGRP, CLR, CT, CTR, ECD |
| 40 |
2016 |
Coated minispheres of salmon calcitonin target rat intestinal regions to achieve systemic bioavailability: Comparison between intestinal instillation and oral gavage. |
CA, CG, i.c, i.j, PEs, SmPill |
| 41 |
2016 |
How Glycosaminoglycans Promote Fibrillation of Salmon Calcitonin. |
GAGs |
| 42 |
2016 |
Monosialoganglioside-GM1 triggers binding of the amyloid-protein salmon calcitonin to a Langmuir membrane model mimicking the occurrence of lipid-rafts. |
--- |
| 43 |
2016 |
Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis. |
--- |
| 44 |
2016 |
Preparation and Evaluation of Enteric-Coated Chitosan Derivative-Based Microparticles Loaded with Salmon Calcitonin as an Oral Delivery System. |
CH, Ch-TBA, MP, TMC |
| 45 |
2015 |
Acylation of salmon calcitonin modulates in vitro intestinal peptide flux through membrane permeability enhancement. |
--- |
| 46 |
2015 |
Chondroitin-based nanoplexes as peptide delivery systems--Investigations into the self-assembly process, solid-state and extended release characteristics. |
CHON, PROT |
| 47 |
2015 |
Design of salmon calcitonin particles for nasal delivery using spray-drying and novel supercritical fluid-assisted spray-drying processes. |
FTIR, HPLC, PXRD, SASD, SD, SEM |
| 48 |
2015 |
Effectiveness of combined salmon calcitonin and aspirin therapy for osteoporosis in ovariectomized rats. |
ASA, BMD, OPG, RANKL |
| 49 |
2015 |
Formulation, stability and pharmacokinetics of sugar-based salmon calcitonin-loaded nanoporous/nanoparticulate microparticles (NPMPs) for inhalation. |
DPI, FPF, MMAD, NPMPs |
| 50 |
2015 |
Microinjection of calcitonin in midbrain periaqueductal gray attenuates hyperalgesia in a chronic constriction injury rat model. |
CCI, CT, CTR, MWT, PAG, TWL |
| 51 |
2015 |
Organic arsenicals as efficient and highly specific linkers for protein/peptide-polymer conjugation. |
--- |
| 52 |
2015 |
Strategic approaches for enhancement of in vivo transbuccal peptide drug delivery in rabbits using iontophoresis and chemical enhancers. |
NAC, SDGC |
| 53 |
2015 |
The inhibitory effect of salmon calcitonin on intervertebral disc degeneration in an ovariectomized rat model. |
BMD, MMP, SHAM |
| 54 |
2015 |
Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials. |
JSN, JSW, KL, OA, PBO, WOMAC |
| 55 |
2014 |
A hyaluronic acid-salmon calcitonin conjugate for the local treatment of osteoarthritis: chondro-protective effect in a rabbit model of early OA. |
HA, IA, MMP, OA |
| 56 |
2014 |
A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats. |
DACRA, DIO, ZDF |
| 57 |
2014 |
Decline in calcitonin receptor expression in osteocytes with age. |
CTR, DMP1, IL-6, MEPE, PTH, SHAM, SOST |
| 58 |
2014 |
Design and evaluation of solid lipid nanoparticles modified with peptide ligand for oral delivery of protein drugs. |
CSK, IRQ, SLNs |
| 59 |
2014 |
Effect of lyophilization on liposomal encapsulation of salmon calcitonin. |
P-NMR |
| 60 |
2014 |
Encapsulation into PEG-liposomes does not improve the bioavailability of pulmonary delivered salmon calcitonin. |
PEG |
| 61 |
2014 |
Formulation and evaluation of novel reverse microemulsions containing salmon calcitonin in hydrofluoroalkane propellants. |
FPF, NGI, pMDIs, TSI |
| 62 |
2014 |
Intermolecular interactions between salmon calcitonin, hyaluronate, and chitosan and their impact on the process of formation and properties of peptide-loaded nanoparticles. |
CMR, CS, HA, MMR, NP |
| 63 |
2014 |
Investigation of coco-glucoside as a novel intestinal permeation enhancer in rat models. |
CG, FD4, HCA |
| 64 |
2014 |
Native metastable prefibrillar oligomers are the most neurotoxic species among amyloid aggregates. |
CD, EF-TEM, SEC |
| 65 |
2014 |
Novel application of polioviral capsid: development of a potent and prolonged oral calcitonin using polioviral binding ligand and Tat peptide. |
CPPs |
| 66 |
2014 |
Oral salmon calcitonin enhances insulin action and glucose metabolism in diet-induced obese streptozotocin-diabetic rats. |
DIO, DIO-STZ |
| 67 |
2014 |
Prolonged calcitonin receptor signaling by salmon, but not human calcitonin, reveals ligand bias. |
hCT |
| 68 |
2014 |
Prolonged hypocalcemic effect by pulmonary delivery of calcitonin loaded poly(methyl vinyl ether maleic acid) bioadhesive nanoparticles. |
--- |
| 69 |
2014 |
Self-assembled hyaluronate/protamine polyelectrolyte nanoplexes: synthesis, stability, biocompatibility and potential use as peptide carriers. |
HA, NPs, PROT |
| 70 |
2014 |
The role of the area postrema in the anorectic effects of amylin and salmon calcitonin: behavioral and neuronal phenotyping. |
AP, DBH, TPH, VGLUT2 |
| 71 |
2013 |
A novel spectrofluorimetric method for the determination of calcitonin in ampules through derivatization with fluorescamine. |
HPLC |
| 72 |
2013 |
A permeation enhancer for increasing transport of therapeutic macromolecules across the intestine. |
PPS |
| 73 |
2013 |
An intra-articular salmon calcitonin-based nanocomplex reduces experimental inflammatory arthritis. |
HA, IA, MMPs, NPs, OA, RA |
| 74 |
2013 |
Conjugation-induced fluorescent labeling of proteins and polymers using dithiomaleimides. |
DTMs |
| 75 |
2013 |
Mucoadhesive intestinal devices for oral delivery of salmon calcitonin. |
EC |
| 76 |
2013 |
NMR investigations of structural and dynamics features of natively unstructured drug peptide - salmon calcitonin: implication to rational design of potent sCT analogs. |
NMR |
| 77 |
2013 |
Oral salmon calcitonin protects against impaired fasting glycemia, glucose intolerance, and obesity induced by high-fat diet and ovariectomy in rats. |
HFD, HOMA-IR, IR |
| 78 |
2013 |
Orally delivered salmon calcitonin-loaded solid lipid nanoparticles prepared by micelle-double emulsion method via the combined use of different solid lipids. |
SA, SLNs, TP |
| 79 |
2013 |
PHEA-graft-polymethacrylate supramolecular aggregates for protein oral delivery. |
SAs |
| 80 |
2013 |
Role of aromatic residues in amyloid fibril formation of human calcitonin by solid-state 13C NMR and molecular dynamics simulation. |
CT, hCT |
| 81 |
2013 |
Salmon calcitonin use and associated cancer risk. |
FDA |
| 82 |
2013 |
Transdermal absorption and stability enhancement of salmon calcitonin by Tat peptide. |
CPPs, SC, Tat |
| 83 |
2012 |
Delivery of salmon calcitonin using a microneedle patch. |
MNs |
| 84 |
2012 |
Direct peptide bioconjugation/PEGylation at tyrosine with linear and branched polymeric diazonium salts. |
mPEGs |
| 85 |
2012 |
In vitro and in vivo characterisation of PEG-lipid-based micellar complexes of salmon calcitonin for pulmonary delivery. |
--- |
| 86 |
2012 |
In vivo iontophoretic delivery of salmon calcitonin across microporated skin. |
ITP, MN |
| 87 |
2012 |
Investigations into the fate of inhaled salmon calcitonin at the respiratory epithelial barrier. |
--- |
| 88 |
2012 |
Metal ions as cofactors for aggregation of therapeutic peptide salmon calcitonin. |
--- |
| 89 |
2012 |
Mice over-expressing salmon calcitonin have strongly attenuated osteoarthritic histopathological changes after destabilization of the medial meniscus. |
DMM, OA, Tg, WT |
| 90 |
2012 |
Minimizing acylation of peptides in PLGA microspheres. |
CMCS, HPLC, hPTH, OCT, PLGA |
| 91 |
2012 |
Noncovalent PEGylation: different effects of dansyl-, L-tryptophan-, phenylbutylamino-, benzyl- and cholesteryl-PEGs on the aggregation of salmon calcitonin and lysozyme. |
HEWL, PEGs, Trp |
| 92 |
2012 |
Oral salmon calcitonin attenuates hyperglycaemia and preserves pancreatic beta-cell area and function in Zucker diabetic fatty rats. |
ZDF |
| 93 |
2012 |
Oral salmon calcitonin improves fasting and postprandial glycemic control in lean healthy rats. |
HOMA-IR, OGTT |
| 94 |
2012 |
Polymeric dibromomaleimides as extremely efficient disulfide bridging bioconjugation and pegylation agents. |
PEG, TCEP |
| 95 |
2012 |
Salmon calcitonin-loaded Eudragit and Eudragit-PLGA nanoparticles: invitro and invivo evaluation. |
NaTDC |
| 96 |
2012 |
Stability and structure of protein-lipoamino acid colloidal particles: toward nasal delivery of pharmaceutically active proteins. |
LP, rhEPO, rhGH |
| 97 |
2012 |
Synthesis, characterization and evaluation of bone targeting salmon calcitonin analogs in normal and osteoporotic rats. |
BMD, BP, ELISA, HA, MALDI-TOF, micro-CT |
| 98 |
2012 |
The use of polyion complex micelles to enhance the oral delivery of salmon calcitonin and transport mechanism across the intestinal epithelial barrier. |
mPEG-g-AA, PIC |
| 99 |
2012 |
Ultraviolet Resonance Raman spectroscopy used to study formulations of salmon calcitonin, a starch-peptide conjugate and TGF-beta3. |
TCP, TGF-beta3, UVRR |
| 100 |
2011 |
A new method to increase selectivity of transglutaminase mediated PEGylation of salmon calcitonin and human growth hormone. |
Gln, hGH, MTGase, PEG |
|
A Search Service for Abbreviation / Long Form
